Irene Ghobrial

A historic day for myeloma!! After 5 decades of research. European Commission / EMA approves Daratumumab as the first ever approved treatment for high risk smoldering myeloma based on the results of the AQUILA trial. @thanosdimop @PlasmaCellPete globenewswire.com/news-release/2…

Very well-deserved indeed!! Congrats Drs. @mvmateos and @ElenaZamagni ! Excited for #IMS25 @Myeloma_Society 👏 #MMsm #woMMen

@Myeloma_Society awards announced to celebrate Women in Myeloma🎉🎉well deserved achievements @mvmateos & @ElenaZamagni

Excited to share a milestone published in @NatureMedicine from our decade-long effort to build The Human Phenotype Project, a unique longitudinal cohort with unmatched depth of clinical and multi-omic profiling, enabling truly predictive, personalized medicine. Led together with…

Really valuable resource in @NatureCellBio from @Nina_CabezasW and team - Metabolomic and lipidomic profiling of human hematopoietic stem and progenitor cells: nature.com/articles/s4155…

🚨 New in Nature Medicine: “Noncanonical and mortality-defining toxicities of CAR T cell therapy” As CAR-T moves beyond heme malignancies, we need a deeper understanding of rare & long-term toxicities. 🔗 nature.com/articles/s4159… PDF: rdcu.be/ewqLH

1/11 Our study on subclonal immune evasion in non-small cell lung cancer has just been published in @Cancer_Cell cell.com/cancer-cell/fu…

Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+ #mmsm ⁦@RomanosSP⁩ ⁦⁦@IrenemGhobrial⁩ #mmsm ashpublications.org/blood/article/…

6/ The real prize? Actionable insight: Regulatory rewiring Therapy resistance states Cell fate trajectories that matter in disease

5/ Too many papers are stuck in descriptive mode: UMAPs and violin plots Marker genes and dot plots A sea of clusters with no anchor to biology

Very relevant and beautiful work @TimCoorens! Congratulations!

Online Now: Subclonal immune evasion in non-small cell lung cancer dlvr.it/TLkxG2

Forty years after the first effort to extract mummy DNA, researchers have finally generated a full genome sequence from an ancient Egyptian go.nature.com/3TYRum9

FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for treatment of relapsed/refractory multiple myeloma in patients who have received at least 4 lines of prior therapy #mmsm ⁦@IMFmyeloma⁩ ⁦@theMMRF⁩ ⁦@HealthTree⁩ pharmacytimes.com/view/fda-appro…

Thanks for posting Mike for posting and Linda for writing it’s critical to take this guidance seriously and to perform these test with good quality control to ensure patients receive optimum therapy - we should now move on to a molecular based approach

FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies #mmsm #lymsm fda.gov/vaccines-blood…

An AI model developed by Google DeepMind could help scientists make sense of the non-protein-coding part of the genome go.nature.com/4k4EcPF

Thank you Vincent! It was a huge and long (>8 years) team effort, but truly worthy. Thank you for your continued support! This is only the beginning. A lot to be done in the future, and I foresee many more years of fruitful work by the i2TEAMM #mmsm

Amazing accomplishment!! Kudos to you and Jesus San Miguel and @BrunoPaiva_UNAV for your leadership! And to the @IMFmyeloma team and I2TEAMM investigators and all our Pharma partners.

Major Regulatory Milestone in MM: In response to an application by I2TEAMM and @IMFmyeloma, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! @VincentRK